TripAdvisor (TRIP): Stronger travel trends are emerging as evidenced by robust results from the airlines, Expedia (EXPE), Las Vegas Sands (LVS) and Priceline (PCLN) this earnings season. This should bode well for often beaten down TripAdvisor (TRIP). Shares are down 25% in 2016 on 2 consecutive weaker than expected quarterly results. TripAdvisor operates in a very competitive online travel agency market that is largely a two horse race between Expedia and Priceline. TRIP is beginning to close the gap though with the acquisition of CityMaps and a new more user friendly website. Expectations have still edged lower in the past 3 months with analysts calling for flat earnings growth and a 6% increase on the top line.

Jazz Pharmaceuticals (JAZZ): Jazz Pharmaceuticals along with the rest of the healthcare industry have suffered a down year heading into this pivotal election. Shares of Jazz are down nearly 25% in the past 12 months on a string of weaker than expected financial results. Its key products should continue to gain traction but that will be offset by near term headwinds such as supply chain disruptions, patent litigations and an overall downturn in the industry. Analysts at Estimize still believe Jazz can deliver a slight improvement from the prior quarter with a 7% increase on the bottom line and 15% on the top.